Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Inventory (2023 - 2025)

Historic Change in Inventory for Krystal Biotech (KRYS) over the last 3 years, with Q4 2025 value amounting to $1.1 million.

  • Krystal Biotech's Change in Inventory fell 8377.55% to $1.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.3 million, marking a year-over-year decrease of 4720.75%. This contributed to the annual value of $6.3 million for FY2025, which is 4720.75% down from last year.
  • Per Krystal Biotech's latest filing, its Change in Inventory stood at $1.1 million for Q4 2025, which was down 8377.55% from $4.7 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Change in Inventory ranged from a high of $6.5 million in Q4 2024 and a low of -$880000.0 during Q2 2025
  • Moreover, its 3-year median value for Change in Inventory was $1.4 million (2025), whereas its average is $2.1 million.
  • Data for Krystal Biotech's Change in Inventory shows a peak YoY increase of 122540.65% (in 2024) and a maximum YoY decrease of 15849.89% (in 2024) over the last 5 years.
  • Over the past 3 years, Krystal Biotech's Change in Inventory (Quarter) stood at $492000.0 in 2023, then soared by 1225.41% to $6.5 million in 2024, then crashed by 83.78% to $1.1 million in 2025.
  • Its Change in Inventory was $1.1 million in Q4 2025, compared to $4.7 million in Q3 2025 and -$880000.0 in Q2 2025.